Health

FDA Approves Sunharbo (asundexian) in Combination with Antiplatelet Therapy for Secondary Stroke Prevention

DailyTrendDailyTrend
Nov 10, 2026 - 20:00
 0  0
WHIPPANY, N.J.-- November 9, 2026 -- Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved Sunharbo® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicated in combination with...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

Susie Wiles, Trump’s Chief of Staff, Is Accused of Blocking Health Policies to Attract Donations

Susie Wiles, Trump’s Chief of Staff, Is Accused of Bloc...

DailyTrend Nov 6, 2026  0  1

MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication

MedWatch Alert: FDA Requires Safety Labeling Changes fo...

DailyTrend Nov 9, 2026  0  1

What a Democratic Congress Could Mean for Science

What a Democratic Congress Could Mean for Science

DailyTrend Nov 6, 2026  0  1

Eugia US LLC (f/k/a Auro Medics Pharma LLC) Issues Voluntary Nationwide Recall of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) Due to Presence of Particulate Matter

Eugia US LLC (f/k/a Auro Medics Pharma LLC) Issues Volu...

DailyTrend Nov 9, 2026  0  0

MedWatch Alert: FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy

MedWatch Alert: FDA Investigating Serious Risk of Malig...

DailyTrend Nov 9, 2026  0  0

FDA Approves Pimjetmi (pimicotinib) for Patients with T...

DailyTrend Nov 10, 2026  0  0